Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR
CompanyDrug

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline
CompanyDeals

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B
CompanyDrug

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation
Policy / Regulatory

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC
CompanyDrug

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China
CompanyDrug

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide
CompanyDrug

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide

CStone Pharmaceuticals Launches CS2009 Phase II Trial in Australia
CompanyDrug

Stone Pharmaceuticals Launches CS2009 Phase II Trial in Australia

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein
CompanyDrug

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration
CompanyDeals

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle
Policy / Regulatory

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic
CompanyDrug

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic